ClinicalTrials.gg
CompletedNCT07358949Updated Nov 20, 2026

Feasibility and Acceptability of Point of Care Rapid Syphilis Testing Among Patients Seeking Family Planning Services in Hawai'i

An observational study in Syphilis Infection, sponsored by Queen's Medical Center. Completed at 1 site in United States. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Queen's Medical Center · Observational

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
51
Ages
14 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Syphilis with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Syphilis · United States.

Enrollment
9th of 10
51 · median 275
Started
2026
with 5 others
Observational
10 of 39
3 open now
Registered
37th of 39
by date

Among the 39 studies in Syphilis with a site in United States, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 6 that started in 2026, is one of 10 observational ones, and was the 37th registered.

Syphilis

126 studies on the registry are indexed under Syphilis; 33 are open to participants now.

Browse Syphilis studies →

Open to participants now

13 of the 39 studies in Syphilis with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Syphilis studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 11 take children under 18; 12 take healthy volunteers.

This study: 14 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Syphilis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to see if rapid syphilis testing at the time of a family planning (contraception or abortion) visit is acceptable and practical for patients.

This study involves a fingerstick blood sample for syphilis testing during a family planning visit. Results will be ready in 10-15 minutes.

Potential Benefits

  • Participants can find out whether they are syphilis positive or negative within the visit, as soon as 10-15 minutes of the finger stick. Typically, syphilis testing results take several days.
  • If positive, there is the option of starting treatment within the same day.

Potential Risks

  • The study team will do everything possible to protect participants' privacy, including removing names and other identifiable information from study materials, however this is still a small chance there may be a breach of privacy during the study.
  • Physical risks of fingerstick are exceptionally rare when sterile technique is used. The study team will be using all best practices to reduce risk of infection or injury.
  • There is a risk of discomfort or pain with fingerstick collection. The risk of scarring is usually only associated with repeat draws, for example in patients with diabetes who have to do fingerstick draws multiple times per day.
  • There is a very small chance that the positive result is incorrect (also known as a "false positive"), meaning the participant does not actually have syphilis. To confirm the result, the investigators recommend that any positive rapid syphilis result be followed up with a blood test at the lab.

Cost for Participation

o There is no direct cost to participate in this study. After consent is signed, the participant received renumeration of $50 in form of gift card. If the participant tests positive for a syphilis infection, the participant or their health insurance will be responsible cover the costs of this medical treatment. If they do not have access to health insurance, the study team will connect the participant with agencies that have assisted patients with treatment at a reduced cost or free of cost.

Read the detailed description

This is a nonrandomized feasibility study of a clinician-administered point of care rapid syphilis test. The study will take place within the Queen's Medical Center Options Clinic, where the University of Hawai'i Complex Family Planning program is based. The Options Center is a primary referral site for abortion throughout Hawai'i. This study aims to evaluate whether the Syphilis Health Check (SHC), an FDA-approved rapid, point-of-care syphilis test, is feasible and acceptable to patients and providers at a university-associated family planning clinic in Hawai'i. Rapid syphilis testing will be offered to sexually active adults seeking abortion or contraception services. Positive results will be followed by laboratory-based syphilis testing. The investigators hypothesize that rapid syphilis testing at the family planning clinic will be feasible and acceptable to both patients and staff.

If the patient expresses interest in syphilis testing, a research associate will describe the study in further detail and obtain informed consent via a paper-based informed consent document.

All study personnel will undergo the SHC training, which includes an online module and quiz available on the SHC website. Study personnel who are certified to collect the SHC will collect the specimen via fingerstick using a sterile lancet. They will collect the blood using the pipette provided in each kit, then add the blood to the sample well of the SHC cassette. They will then add four drops of diluent to the sample well. The study personnel can read the result at the 10-minute mark, and no later than 15 minutes. Any line in the 'T' zone, even if faint, accompanied by a line in the 'C' zone, will be interpreted as a positive result. The study personnel, if not a family planning provider, will inform the physician of all test results. All participants with a positive SHC test will be recommended to get confirmatory serological testing. All participants will receive their results before the end of their family planning visit.

Traditional serological testing requires external laboratory equipment and facilities. The SHC is read in the clinic without additional equipment or laboratory technicians, thus expediting time from specimen collection to diagnosis. Participants with positive SHC results will require more thorough evaluation to stage and determine appropriate treatment. The physician will conduct a detailed health history and physical exam. The SHC is a qualitative treponemal test; therefore, after their counseling and discussion with the physician, the participant will be asked to go to the laboratory to draw blood for an RPR, for which there is no rapid test. The RPR acts as a confirmatory test while also providing quantitative information to monitor treatment effectiveness.

If the participant is pregnant and desires to continue with pregnancy, then the patient will be referred to a pharmacy or clinic that can administer Bicillin. These may include Queen's pharmacy, other pharmacy, Healthy Mothers Healthy Babies, PATH Clinic, Diamond Head STI Clinic. Additional appointments as needed will be made to complete the treatment (up to 3 total doses of Bicillin). If there is still an ongoing shortage and/or recall of Bicillin at the time of study initiation, the physician will call 808-833-9281 to request an appointment with the Hawai'i Department of Public Health STI/HIV Clinic for assistance with where to refer the patient for Bicillin treatment options. At the time of writing, Bicillin is prioritized for pregnant individuals only. For participants with positive SHC who are terminating pregnancy or who are not pregnant, the alternative treatment is doxycycline per CDC guidelines. The physician will prescribe 2 to 4 weeks of doxycycline 100mg BID based on the staging of infection in accordance with CDC guidelines. Patients will be counseled on increased sun sensitivity with longer durations of doxycycline use, and recommend sun protection.

Positive SHC results that have been confirmed with positive serum RPR will be reported to the State of Hawai'i Department of Health using the Sexually Transmitted Infection Confidential Case Report within three business days per state guidelines, either through mail, fax, or phone .

For partner notification, the study physician will provide resources for patients to share with their partner(s) for testing options. Options will include: 1) the patient informs their sexual partner(s) directly or anonymously through a text-based service; 2) the physician informs their sexual partner(s) via a text-based service; 3) deferring to the public health department to inform their sexual partner(s) through their intervention specialist team.

03

Conditions studied

  • Syphilis Infection

Browse trials for

Keywords

  • feasibility
  • rapid syphilis testing
  • family planning
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The Queens Options Center serves as a referral center for family planning services for patients throughout the state. From prior literature, the patients most impacted by persistent or continued syphilis infections are those who are structurally vulnerable, including those who are under- or uninsured, experiencing poverty, unhoused, or actively using substances. By screening universally, we may decrease the stigmatization associated with individual behavior-based screening. We acknowledge that there is a risk of increased false positives by screening universally . To mitigate this, we recommend that a participant with a positive rapid test also obtain serological testing with RPR, which is already required for treatment monitoring. As stated above, prior studies have established that the sensitivity and specificity of the SHC are greater than 95%.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 14 years or older
  • Seeking or abortion services
  • Sexually active (engages in any form of sexual activity with another person)
  • Denies history of syphilis infection
  • Can speak and read English
  • Displays capacity for

Exclusion criteria

Exclusion Criteria:

  • Confirmed history (by patient report or medical records) of syphilis
  • Home address outside Hawai'i
  • Currently incarcerated

Number of Subjects:

Recommendations for sample size in pilot studies range from 70 to 100 patients.28 Given this is a nonrandomized feasibility study with no comparator (i.e., to a control or to serological testing), we aim to enroll 50 to 75 participants to support analysis for correlation between variables while being able to achieve relatively small confidence intervals. This number takes into account the practical considerations of study personnel resources and in-person patient volume in our clinic. All patients eligible for the rapid syphilis testing will be approached for study participation.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
51 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testRapid Syphilis Test

    This study aims to evaluate whether the Syphilis Health Check (SHC), an FDA-approved rapid, point-of-care syphilis test, is feasible and acceptable to patients and providers at a university-associated family planning clinic in Hawai'i. SHC is specific for detecting Treponema pallidum antibodies in serum, plasma, or whole blood via a rapid immunochromatographic test. It has a sensitivity of 95-99% and a specificity of 94-97%, and has been studied in pregnant patients. The test costs approximately $10, takes 10-15 minutes to yield results, has a shelf life of 30 months, and remains stable at room temperature. The assay can be used as an initial screening test or in conjunction with a non-treponemal laboratory test. Treatment with antibiotics can be started immediately with a positive SHC test.

06

What researchers measure

Primary outcomes

  1. Acceptability and Feasibility of Rapid Syphilis Testing

    We will assess feasibility with a combination of quantitative and qualitative methods, in accordance with guidelines put forth by Teresi et al for feasibility pilot studies. Outcomes: * Number of eligible participants * Number of participants who completed SHC testing * Number of participants who agreed to SHC testing * Number of participants able to obtain SHC result * To calculate feasibility, the proportion of all eligible patients who completed testing will be determined. * To calculate completion rate of the SHC tests using the number of participants who were able to obtain an SHC result divided by the number of participants who agreed to rapid syphilis testing. Descriptive statistics will be used to assess acceptibility.

    Time frame: 12 months

Secondary outcomes

  1. Secondary Outcomes

    Secondary outcomes: * Number of family planning patients who had syphilis testing in the past year. * Number of family planning patients who test positive for syphilis. * Time (in days) to prescribe treatment after positive syphilis test.

    Time frame: 12 months

  2. Assess the acceptability and feasibility of a point-of-care rapid syphilis testing in a university-affiliated family planning clinic.

    We will assess feasibility with a combination of quantitative and qualitative methods, in accordance with guidelines put forth by Teresi et al for feasibility pilot studies. Outcomes: * Number of eligible participants * Number of participants who completed SHC testing * Number of participants who agreed to SHC testing * Number of participants able to obtain SHC result * To calculate feasibility, the proportion of all eligible patients who completed testing will be determined. * To calculate completion rate of the SHC tests using the number of participants who were able to obtain an SHC result divided by the number of participants who agreed to rapid syphilis testing. * Descriptive statistics will be used to assess acceptibility.

    Time frame: 12 months

07

Study locations

1 site
  • Queen's Medical Center, 1004 Clinic POB1
    Honolulu, Hawaii 96813, United States
08

References and documents

Publications

  • Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for Designing and Evaluating Feasibility Pilot Studies. Med Care. 2022 Jan 1;60(1):95-103. doi: 10.1097/MLR.0000000000001664. PubMed 34812790 ↗
  • Harvey L, Jacka B, Bazerman L, Thomas A, Moody M, Irvin R, Beckwith CG. Feasibility and Performance of a Point-of-Care Hepatitis C RNA Assay in a Community Supervision Cohort. JAMA Netw Open. 2024 Oct 1;7(10):e2438222. doi: 10.1001/jamanetworkopen.2024.38222. PubMed 39374019 ↗
  • Nuwagaba-Biribonwoha H, Simelane S, Sithole T, Dlamini S, Mavimbela M, Dube N, Mamba S, Mamba M, Sahabo R, El Sadr WM, Abrams EJ, Justman J. Feasibility and Acceptability of Point-of-Care Testing for Sexually Transmitted Infections in Outpatient Clinics Offering Integrated Services in Eswatini. Sex Transm Dis. 2024 Nov 1;51(11):743-749. doi: 10.1097/OLQ.0000000000001997. Epub 2024 Jun 11. PubMed 38860665 ↗
  • Stafford I, Bakunas C, Haydamous J, Mosqueda A, Klausner JD, Mena L, Blackwell SC. Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department. Sex Transm Dis. 2025 Jun 1;52(6):352-355. doi: 10.1097/OLQ.0000000000002131. Epub 2024 Dec 24. PubMed 39718531 ↗
  • Missed Opportunities for Prevention of Congenital Syphilis -United States, 2018. Pediatr Infect Dis J. 2020 Nov 1;39(11):1062. doi: 10.1097/INF.0000000000002833. No abstract available. PubMed 33369594 ↗
  • Corrigendum to "Syphilis Screening: A Review of the Syphilis Health Check Rapid Immunochromatographic Test". J Pharm Technol. 2020 Apr;36(2):91. doi: 10.1177/8755122520904797. Epub 2020 Jan 29. PubMed 34752533 ↗
  • Cao W, Thorpe PG, O'Callaghan K, Kersh EN. Advantages and limitations of current diagnostic laboratory approaches in syphilis and congenital syphilis. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1339-1354. doi: 10.1080/14787210.2023.2280214. Epub 2023 Nov 24. PubMed 37934903 ↗
  • Chan EYL, Smullin C, Clavijo S, Papp-Green M, Park E, Nelson M, Giarratano G, Wagman JA. A qualitative assessment of structural barriers to prenatal care and congenital syphilis prevention in Kern County, California. PLoS One. 2021 Apr 1;16(4):e0249419. doi: 10.1371/journal.pone.0249419. eCollection 2021. PubMed 33793630 ↗
  • Plotzker RE, Burghardt NO, Murphy RD, McLean R, Jacobson K, Tang EC, Seidman D. Congenital syphilis prevention in the context of methamphetamine use and homelessness. Am J Addict. 2022 May;31(3):210-218. doi: 10.1111/ajad.13265. Epub 2022 Mar 27. PubMed 35340101 ↗
  • McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol. 2014 Dec;57(4):635-43. doi: 10.1097/GRF.0000000000000070. PubMed 25286295 ↗
  • Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005 Feb 1;191 Suppl 1:S115-22. doi: 10.1086/425280. PubMed 15627221 ↗
  • Johnson KA, Snyder RE, Tang EC, de Guzman NS, Plotzker RE, Murphy R, Jacobson K. Geospatial Social Determinants of Health Correlate with Disparities in Syphilis and Congenital Syphilis Cases in California. Pathogens. 2022 May 6;11(5):547. doi: 10.3390/pathogens11050547. PubMed 35631068 ↗
  • Gan A, Shintaku KM, Begue RE. Gaps in the Care of Maternal and Congenital Syphilis in Hawai'i, 2022-2023. Pediatr Infect Dis J. 2025 Dec 1;44(12):e440-e445. doi: 10.1097/INF.0000000000004931. Epub 2025 Aug 6. PubMed 40829011 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Nov 2026, 3 months.

Of 17 observational studies under Syphilis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 3 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Aug 2027 → Nov 2026 and completion Dec 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 22, 2026
StartActual
Jul 20, 2026
Primary completionActual
Nov 10, 2026was Aug 2027
CompletionActual
Nov 10, 2026was Dec 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Primary completion
Aug 1, 2027→Nov 10, 2026 (actual)
Nov 20, 2026
Study completion
Dec 2027→Nov 10, 2026 (actual)
Nov 20, 2026
Enrollment
70 (estimated)→51 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Primary completion Aug 1, 2027→Nov 10, 2026 (now actual)
    Study completion Dec 2027→Nov 10, 2026 (now actual)
    Enrollment 70 (estimated)→51 (actual)
    + 3 other changes: responsible party, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07358949
Lead sponsor
Queen's Medical Center
Responsible party
Mary Tschann (Complex Family Planning Scientist, Queen's Medical Center) — Principal investigator
First posted
Jan 22, 2026
Start date
Jul 20, 2026
Primary completion
Nov 10, 2026
Completion
Nov 10, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion